GeneMatrix vs Thermo Fisher Scientific: Fair Value & Quality
Both stocks run through our valuation models. Here is how GeneMatrix (109820) and Thermo Fisher Scientific (TMO) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: GeneMatrix trades at KRW 1,482 versus a fair value of KRW 732 (-51%), while Thermo Fisher Scientific trades at $594 versus $308 (-48%).
GeneMatrix
109820.KQ · KRW · Health Care
-51%
upside to fair value
overvalued
PriceKRW 1,482
Fair ValueKRW 732
Quality60/100
Thermo Fisher Scientific
TMO · USD · Health Care
-48%
upside to fair value
overvalued
Price$594
Fair Value$308
Quality63/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
GeneMatrixThermo Fisher Scientific
Valuation
—P/E (TTM)29.5×
—P/S (TTM)4.41×
—P/B3.74×
—EV/EBITDA20.0×
—PEG1.74×
—Dividend yield0.3%
—Dividend per share$1.76
Profitability
-44%Net margin15%
-46%Operating margin18%
-16%Return on equity14%
-6%Return on assets5%
Growth
-5%Revenue growth (YoY)6%
-1.7%Avg. growth/yr (3Y)-0.3%
-7.7%Avg. growth/yr (5Y)6.7%
Balance & size
—Debt / equity0.67×
$19MMarket cap$199B
weakGrowth qualityhealthy
Thermo Fisher Scientific leads: 0 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
GeneMatrixof which business quality 60 · market factors 16Thermo Fisher Scientificof which business quality 60 · market factors 65
ProfitabilityMargins and returns on capital today
13
43
Quality GrowthAre margins and returns improving?
68
31
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
100
79
Low VolatilityCalm price path (market factor)
43
68
MomentumPrice trend over the last 3–12 months (market factor)
5
58
52W MomentumDistance to the 52-week high (market factor)
5
72
Net IssuanceBuybacks instead of dilution
82
97
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
GeneMatrix
DCF ModelsKRW 979
MultiplesKRW 912
Asset-BasedKRW 586
Growth DCFKRW 1,033
7 of 7 models see the stock below the current price.
Thermo Fisher Scientific
DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341
24 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
GeneMatrix
Bear KRW 492Fair Value KRW 732Bull KRW 971
KRW 1,482 = current price (white tick)
Thermo Fisher Scientific
Bear $175Fair Value $308Bull $385
$594 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
GeneMatrix · Health Care
Quality score60 · above median
Fair value upside-51% · below median
Thermo Fisher Scientific · Health Care
Quality score63 · above median
Fair value upside-48% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: GeneMatrix trades at KRW 1,482 versus a fair value of KRW 732 (-51%), while Thermo Fisher Scientific trades at $594 versus $308 (-48%).
Thermo Fisher Scientific has the higher quality score (63/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
